Serum pentraxin 3 as a clinical biomarker of branch atheromatous disease: a marker of brain ischaemia or an atherotrombosis marker?

2020 ◽  
Vol 27 (7) ◽  
pp. 1100-1101
Author(s):  
A. Tuttolomondo ◽  
A. Pinto
Keyword(s):  
Pentraxin 3 ◽  
Brain Ischaemia ◽  
Branch Atheromatous Disease ◽  
Clinical Biomarker

Elevated serum pentraxin 3 levels might predict the diagnosis of branch atheromatous disease at a very early stage

2020 ◽  
Vol 27 (7) ◽  
pp. 1279-1284 ◽  
Author(s):  
I. Ninomiya ◽  
M. Kanazawa ◽  
M. Uemura ◽  
O. Onodera
Keyword(s):  
Early Stage ◽  
Elevated Serum ◽  
Pentraxin 3 ◽  
Branch Atheromatous Disease

Pentraxin 3: A novel biomarker for Heart failure?

2008 ◽  
Vol 7 ◽  
pp. 42-42
Author(s):  
S ABOURAYA ◽  
A ABOURAYA ◽  
M HELMII
Keyword(s):  
Heart Failure ◽  
Pentraxin 3

Statins Pentraxin 3 and Heart Failure: What is the link?

2008 ◽  
Vol 7 ◽  
pp. 187-187
Author(s):  
A ABOURAYA ◽  
S ABOURAYA ◽  
M HELMII
Keyword(s):  
Heart Failure ◽  
Pentraxin 3

Pentraxin-3 as a more sensitive marker of coronary artery disease severity than C-reactive protein

2013 ◽  
Author(s):  
Janusz Szkodzinski ◽  
Bartosz Hudzik ◽  
Aleksander Danikiewicz ◽  
Anna Pietka-Rzycka ◽  
Andrzej Lekston ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Disease Severity ◽  
Pentraxin 3 ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Coronary Artery Disease Severity ◽  
Artery Disease ◽  
Sensitive Marker

scholarly journals Pentraxin 3: A Novel Biomarker for Inflammatory Cardiovascular Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Kenji Inoue ◽  
Tatsuhiko Kodama ◽  
Hiroyuki Daida
Keyword(s):  
Gene Expression ◽  
Cardiovascular Disease ◽  
Pentraxin 3 ◽  
Human Endothelial Cells ◽  
C Reactive Protein ◽  
Physiological Concentration ◽  
Reactive Protein ◽  
Atherosclerotic Lesions ◽  
Human Genes

Numerous studies have recently examined the role of pentraxin 3 (PTX3) in clinical situations. The pentraxin family includes C-reactive protein (CRP); however, unlike CRP, PTX3 is expressed predominantly in atherosclerotic lesions that involve macrophages, neutrophils, dendritic cells, or smooth muscle cells. Interestingly, PTX3 gene expression in human endothelial cells is suppressed to a greater extent by pitavastatin than the expression of 6,000 other human genes that have been examined, suggesting that PTX3 may be a novel biomarker for inflammatory cardiovascular disease. The expression and involvement of PTX3 in cardiovascular diseases are discussed in this paper, along with the characteristics of PTX3 that make it a suitable biomarker; namely, that the physiological concentration is known and it is independent of other risk factors. The results discussed in this paper suggest that further investigations into the potential novel use of PTX3 as a biomarker for inflammatory cardiovascular disease should be undertaken.

scholarly journals FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles

2017 ◽  
Vol 9 (12) ◽  
pp. 797-816 ◽  
Author(s):  
Zhi Yang ◽  
Shuai Jiang ◽  
Yicheng Cheng ◽  
Tian Li ◽  
Wei Hu ◽  
...  
Keyword(s):  
Transcriptional Regulator ◽  
Cancer Development ◽  
Protein Activity ◽  
Stem Cell Maintenance ◽  
Cancer Migration ◽  
Forkhead Box ◽  
Pathological Conditions ◽  
Clinical Biomarker ◽  
Abnormal Cell Proliferation ◽  
Cell Maintenance

Forkhead box C1 (FOXC1) is an essential member of the forkhead box transcription factors and has been highlighted as an important transcriptional regulator of crucial proteins associated with a wide variety of carcinomas. FOXC1 regulates tumor-associated genes and is regulated by multiple pathways that control its mRNA expression and protein activity. Aberrant FOXC1 expression is involved in diverse tumorigenic processes, such as abnormal cell proliferation, cancer stem cell maintenance, cancer migration, and angiogenesis. Herein, we review the correlation between the expression of FOXC1 and tumor behaviors. We also summarize the mechanisms of the regulation of FOXC1 expression and activity in physiological and pathological conditions. In particular, we focus on the pathological processes of cancer targeted by FOXC1 and discuss whether FOXC1 is good or detrimental during tumor progression. Moreover, FOXC1 is highlighted as a clinical biomarker for diagnosis or prognosis in various human cancers. The information reviewed here should assist in experimental designs and emphasize the potential of FOXC1 as a therapeutic target for cancer.

Sign in / Sign up

Export Citation Format

Share Document